(480) 821-2838


(QOPI) Certification program, an affiliate of the American Society of Clinical Oncology - Learn More

Closed Trials

Anti-Emetic Trials:

Anti-Emetic Trial for Patients Receiving First Cycle of a Highly Emetogenic Chemotherapy (HEC)

A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Subjects Receiving Highly Emetogenic Chemotherapy
http://clinicaltrials.gov/ct2/show/NCT02106494?term=C2013-01&rank=1
For questions, please contact 480-398-7671

Brain Cancer Trials:

Newly diagnosed brain metastasis from NSCLC (non-small cell lung cancer)

A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC).
http://clinicaltrials.gov/ct2/show/NCT01657799?term=m10-897&rank=1
For questions, please contact 480-398-7671

Recurrent Glioblastoma Multiforme (GBM)

A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC).
http://clinicaltrials.gov/ct2/show/NCT01657799?term=m10-897&rank=1
For questions, please contact 480-398-7671

Breast Cancer Trials:

Metastatic HER2- / ER- / PR- (Triple Negative) Breast Cancer

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer(mTNBC) – (KEYNOTE-119)
https://clinicaltrials.gov/ct2/show/NCT02555657?term=KEYNOTE-119&rank=1
For questions, please contact 480-398-7671

Advanced or Metastatic HER2- ER+ Breast Cancer

A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
https://clinicaltrials.gov/ct2/show/NCT02422615?term=CLEE011F2301&rank=1
For questions, please contact 480-398-7671

Advanced or Metastatic HER2 negative, HR positive Breast Cancer


This Trial features Dr. Sujith Kalmadi at Ironwood Cancer & Research Centers in the US for enrolling the first subject on study. To view this trial please follow the link.

A Phase 2, Randomized, Open-Label, Two-Arm Study To Assess The Efficacy And Safety Of The Epigenetic Modifying Effects Of CC-486 (Oral Azacitidine) In Combination With Fulvestrant In Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed On An Aromatase Inhibitor
https://clinicaltrials.gov/ct2/show/NCT02374099?term=CC-486-BRSTM-001&rank=1
For questions, please contact 480-398-7671

Advanced or Metastatic HER2 -HR + Breast Cancer

A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment (BELLE 3)
http://clinicaltrials.gov/ct2/show/NCT01633060?term=CBKM120F2303&rank=1
For questions, please contact 480-398-7671

Advanced or Metastatic HER2– HR+ Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
https://clinicaltrials.gov/ct2/show/NCT02246621?term=I3Y-MC-JPBM&rank=1
For questions, please contact 480-398-7671

Newly diagnosed or previously treated HER2 – metastatic breast cancer

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer (INCB 18424-268)
http://clinicaltrials.gov/ct2/show/NCT02120417?term=INCB+18424-268&rank=1
For questions, please contact 480-398-7671

Advanced or metastatic triple negative (HER2 –, ER -, PR -) Breast Cancer

A Study to Evaluate the Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine or Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (tnAcity)
http://clinicaltrials.gov/ct2/show/NCT01881230?term=abi-007&recr=Open&rank=34
For questions, please contact 480-398-7671

Adjuvant treatment for HER2+ Breast Cancer

A Randomized, Multicenter, Open-Label, Phase III  Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT01966471?term=BO28407&rank=1
For questions, please contact 480-398-7671

Advanced or Metastatic HER2 – HR + Breast Cancer

A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
http://clinicaltrials.gov/ct2/show/NCT01958021?term=CLEE011A2301&rank=1
For questions, please contact 480-398-7671

Advanced or metastatic HER2 – and HR+ Breast Cancer

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
http://clinicaltrials.gov/ct2/show/study/NCT01528345?term=CTKI258&rank=8&show_locs=Y#locn
For questions, please contact 480-398-7671

Advanced or metastatic HER2 + and HR + Breast Cancer

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT01491737?term=MO27775&rank=1
For questions, please contact 480-398-7671

Newly diagnosed HER2 + metastatic breast cancer

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B3271002)
http://clinicaltrials.gov/ct2/show/NCT01989676?term=B3271002&rank=1
For questions, please contact 480-398-7671

Advanced or metastatic HER2 – Breast Cancer

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4
http://clinicaltrials.gov/ct2/show/NCT01572727?term=belle+4&rank=1
For questions, please contact 480-398-7671

Metastatic HR+, HER2 negative breast cancer after endocrine therapy

A Study of Palbociclib Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3
http://clinicaltrials.gov/ct2/show/NCT01942135?term=paloma+3&rank=1
For questions, please contact 480-398-7671

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT00968968?term=lapatinib+%26+gsk&rank=22

Previously treated advanced HER2/neu over-expressing Breast Cancer

A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing locally advanced or metastatic breast cancer.
http://clinicaltrials.gov/ct2/show/NCT01007942?term=bolero+3&rank=1

HER2 positive, locally advanced or metastatic breast cancer study

A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MDD-DM1 vs. Capecitabine + Lapatinib in Patients with HER2-positive Locally Advanced or Metastatic Breast Cancer who have received Prior Trastuzumab-Based Therapy
http://clinicaltrials.gov/ct2/show/NCT00829166?term=emilia&rank=1

First line therapy in women with HER2 positive locally advanced or metastatic breast cancer.

A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 positive Locally Advanced or Metastatic Breast Cancer.
http://clinicaltrials.gov/ct2/show/NCT00876395?term=bolero+1&rank=1

First line treatment study of Docetaxel + IMC-1121B or Placebo in Breast Cancer

A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT00703326?term=trio-012&rank=1

Advanced or metastatic HER2+  Breast Cancer

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
http://www.clinicaltrials.gov/ct2/show/NCT01125566?term=1200.75&rank=1

Colorectal Cancer Trials:

Previously treated metastatic colorectal cancer

Study of Ruxolitinib in Colorectal Cancer Patients
http://clinicaltrials.gov/ct2/show/NCT02119676?term=INCB+18424-267&rank=1
For questions, please contact 480-398-7671

Recurrent KRAS & NRAS Wild Type Colorectal Cancer- Chandler location only, referrals available

An Open-Label, Multi-Center, Randomized Phase 1B/2 Study of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer
http://clinicaltrials.gov/ct2/show/NCT01937715?term=B2151007&rank=1
For questions, please contact 480-398-7671

Recurrent KRAS & NRAS Wild Type Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
http://clinicaltrials.gov/ct2/show/NCT01925274?term=B2151005&rank=
For questions, please contact 480-398-7671

Glioblastoma Multiforme Trials:

Recurrent Glioblastoma Multiforme after radiotherapy and Temozolomide

Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
http://clinicaltrials.gov/ct2/show/NCT01934361?term=CBKM120E2102&rank=1
For questions, please contact 480-398-7671

Head & Neck Trials:

Previously Treated Indolent Non-Hodgkin’s Lymphomas

A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732913?term=GS-US-313-0124&rank=1
For questions, please contact 480-398-7671

Treatment for Metastatic Squamous Cell Cancer of the Head and Neck

A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT02252042?term=KEYNOTE-040&rank=1
For questions please contact 480-398-7671

Iron Deficiency Anemia Trials:

Iron Deficiency Anemia

A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer® vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting
http://clinicaltrials.gov/ct2/show/NCT01950247?term=1VIT13032&rank=1
For questions, please contact 480-398-7671

Leukemia Trials:

Treatment for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT02301156?term=UTX-IB-301&rank=1
For questions please contact 480-398-7671

Assessing eligibility for a trial for previously treated Chronic Lymphocytic Leukemia (CLL)

Screening Protocol to Determine High-risk Cytogenetic Features in Patients With Previously-treated CLL That May be Eligible for TG Therapeutics Trial UTX-IB-301
No website available at this time
For questions, please contact 480-398-7671

First line treatment for Chronic Lymphocytic Leukemia (CLL)

A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02320487?term=ML29538&rank=1
For questions please contact 480-398-7671

Treatment for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT02301156?term=UTX-IB-301&rank=1

Screening Protocol available to determine high-risk cytogenetic feature in patients with previously-treated CLL 
For questions please contact 480-398-7671

Lung Cancer Trials:

Second line treatment for advanced or metastatic squamous non-small cell lung cancer (NSCLC)

A Phase II Study of the Combination ofLY3023414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
https://clinicaltrials.gov/ct2/show/NCT02443337?term=I6A-MC-CBBE&rank=1
For questions, please contact 480-398-7671

First line treatment for metastatic/Stage IV Lung Cancer (Non-Squamous)

A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]
https://clinicaltrials.gov/ct2/show/NCT02366143?term=GO29436&rank=1
For questions please contact 480-398-7671

First line treatment for metastatic/Stage IV Lung Cancer (Squamous)

A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
https://clinicaltrials.gov/ct2/show/NCT02367794?term=GO29437&rank=1
For questions please contact 480-398-7671

Third line or higher metastatic non-small cell lung cancer (NSCLC)

A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)
https://clinicaltrials.gov/ct2/show/NCT02352948?term=D4191C00004&rank=1
For questions, please contact 480-398-7671

Maintenance Treatment of Locally Advanced Lung Cancer

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)
http://clinicaltrials.gov/ct2/show/NCT02125461?term=D4191C00001&rank=1
For questions, please contact 480-398-7671

First line treatment for advanced or metastatic non-squamous NSCLC

A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
https://clinicaltrials.gov/ct2/show/NCT02119650?term=INCB+18424-266&rank=1
For questions, please contact 480-398-7671

Second Line Treatment of Metastatic Lung Cancer

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer (SUNRISE)
http://clinicaltrials.gov/ct2/show/NCT01999673?term=PPHM1202&rank=1
For questions, please contact 480-398-7671

Second Line Treatment for Metastatic/Stage IV Lung Cancer (KRAS+ or Squamous)

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02283320?term=BIND-014-007&rank=1
For questions please contact 480-398-7671

Secondly Line Treatment of Advanced Lung Cancer

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
http://clinicaltrials.gov/ct2/show/NCT02093962?term=TH-CR-415&rank=1
For questions, please contact 480-398-7671

Second line treatment for advanced or metastatic adenocarcinoma NSCLC

Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02231164?term=1199.128&rank=1
For questions, please contact 480-398-7671

Recurrent ALK+ Non-Small Cell Lung Cancer

An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity
http://clinicaltrials.gov/ct2/show/NCT01947608?term=CLDK378A2402&rank=1

Second line and third line treatment of metastatic lung cancer (ON HOLD)

An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
http://clinicaltrials.gov/ct2/show/NCT01297491?term=bkm120&rank=11

Second line NSCLC treatment of metastatic squamous cell lung cancer

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy.
http://www.clinicaltrials.gov/ct2/show/NCT01523587?term=1200.125&rank=1

Second or third line treatment of metastatic lung cancer

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
http://clinicaltrials.gov/ct2/show/study/NCT01456325?term=metlung&rank=2&show_locs=Y#locn

First line treatment for metastatic lung cancer

A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination with a Platinum Containing Doublet in Chemotherapy-Naїve Subjects with Stage IV Adenocarcinoma of the Lung.
http://clinicaltrials.gov/ct2/show/NCT01218516?term=morphotek&rank=11

Second or third line treatment of metastatic lung cancer

A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer.
http://clinicaltrials.gov/ct2/show/NCT01362400?term=infinity+pharmaceuticals&rank=3

First line treatment of metastatic lung cancer

A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer http://clinicaltrials.gov/ct2/show/study/NCT01160601?term=peregrine&rank=5#locn

Second line treatment of metastatic lung cancer

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer http://clinicaltrials.gov/ct2/show/NCT01138163?term=peregrine&rank=12

First line treatment for advanced lung cancer – squamous histology

A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT00981058?term=squire&rank=1

Second or third line treatment of metastatic lung cancer

A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression After, or Intolerance to, at Least One Prior Chemotherapy.
http://clinicaltrials.gov/ct2/show/NCT01360554?term=a7471009&rank=1

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment http://clinicaltrials.gov/ct2/results?term=m10-301

First line treatment of metastatic lung cancer

Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT01560104?term=m10-898&rank=1

Lymphoma Trials:

Previously treated Indolent, relapsed, CD20 positive, B-Cell Non-Hodgkin’s Lymphoma

A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy.
http://clinicaltrials.gov/ct2/show/NCT01294579?term=arzerra&recr=Open&rank=4
For questions, please contact 480-398-7671

Previously Treated Indolent Non-Hodgkin’s Lymphomas

A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732913?term=GS-US-313-0124&rank=1
For questions, please contact 480-398-7671

Previously Treated Indolent Non-Hodgkins Lymphomas

A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732926?term=GS-US-313-0125&rank=1
For questions, please contact 480-398-7671

Previously untreated Follicular Lymphoma

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)
http://clinicaltrials.gov/ct2/show/NCT01650701?term=RV-FOL-GELARC-0683C&rank=1
For questions, please contact 480-398-7671

First line treatment for Diffuse Large B-Cell Lymphoma

A Phase III, Multicenter, Randomized Trial Comparing the Efficacy of GA101 in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). http://clinicaltrials.gov/ct2/show/NCT01287741?term=bo21005&rank=1

Adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy.
http://clinicaltrials.gov/ct2/show/NCT00790036?term=pillar+2&rank=1

Relapsed or Recurrent Mantle Cell Lymphoma

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
http://clinicaltrials.gov/ct2/show/NCT01833039?term=ibrutinib+and+mantle+cell&recr=Open&rank=3

Multiple Myeloma Trials:

Previously Untreated Newly diagnosed Multiple Myeloma

MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
http://clinicaltrials.gov/ct2/show/NCT01850524?term=C16014&rank=1
For questions, please contact 480-398-7671

Treatment for Relapsed or Refractory Multiple Myeloma

An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy
http://clinicaltrials.gov/ct2/show/NCT02204553?term=CLBH589DUS94X&rank=1
For questions, please contact 480-398-7671

Previously Untreated Newly diagnosed Multiple Myeloma

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1)
http://clinicaltrials.gov/ct2/show/NCT01335399?term=CA204-006&rank=1
For questions, please contact 480-398-7671

Pancreatic Cancer Trials:

Second line metastatic pancreatic cancer

A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
https://clinicaltrials.gov/ct2/show/NCT02117479?term=INCB+18424-362&rank=1
For questions, please contact 480-398-7671

First line stage IV ductal adenocarcinoma of the pancreas

A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients with Previously Untreated Stage IV Pancreatic Cancer.
http://clinicaltrials.gov/ct2/show/NCT01272791?term=pphm+1002&rank=1

(Hematology) Polycythemia Vera (PV) Trials:

Treatment for Hydroxyurea intolerant or resistant PV patients

Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial)
http://clinicaltrials.gov/ct2/show/NCT01243944?term=response+trial&recr=Open&rank=1

Prostate Trials:

Second line treatment for metastatic castration-resistant prostate cancer

An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy – Early Access Protocol.
http://clinicaltrials.gov/ct2/show/study/NCT01217697?term=abiraterone&recr=

Radiation Therapy Trials:

Breast cancer patients receiving radiation

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis
http://clinicaltrials.gov/ct2/show/NCT02142959?term=408+c+1306&rank=1
For questions, please contact 480-398-7671

Treatment of oral mucositis in patients receiving chemoradiation

A Randomized, Multicenter, Prospective, Double-Blind, Sham-Controlled, Study to Evaluate the Efficacy of MuGard™ Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis  in Subjects receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck.
http://clinicaltrials.gov/ct2/show/NCT01283906?term=mugard&rank=1

Registry Trials:

Observational study of patients with advanced melanoma

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)
http://clinicaltrials.gov/ct2/show/study/NCT01511913?term=IMAGE+melanoma&rank=1
For questions, please contact 480-398-7671

 Observational study of patients with advanced melanoma

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)
http://clinicaltrials.gov/ct2/show/NCT01511913?term=CA184-143&rank=1

A data collection study for patient receiving Provenge®

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
http://clinicaltrials.gov/ct2/show/NCT01306890?term=proceed&rank=4